Biomarkers for the molecular classification of bacterial infection

Patent metadata

Field	Value
Publication number	US-9850539-B2
Application number	US-201514880668-A
Country	US
Kind code	B2
Filing date	Oct 12, 2015
Priority date	Mar 15, 2013
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.

First claim

What is claimed is:

1. A method of identifying and treating a subject suspected of having a bacterial blood stream infection (BSI), the method comprising:
a) determining in a peripheral blood cell sample of the subject the gene expression levels of two or more biomarkers selected from the group consisting of the biomarkers of Factor 20 and Factor 74 listed in Table 8 and Table 10, wherein the determined gene expression levels are RNA expression levels determined by microarray analysis, or PCR, or a combination thereof; and
b) administering an effective amount of antibiotic therapy to treat the subject identified as having a bacterial BSI, wherein the subject is identified as having the bacterial BSI when the gene expression levels of the two or more biomarkers are different than the gene expression levels for the biomarkers in a control with known bacterial infection status.

2. The method of claim 1 , wherein the bacterial blood stream infection is S. aureus BSI.

3. The method of claim 1 , wherein the bacterial blood stream infection is E. coli BSI.

4. The method of claim 1 , wherein the control is a healthy subject.

5. The method of claim 1 , wherein the subject is a mammal.

6. A method of distinguishing and treating Staphylococcus aureus blood stream infection (BSI) from Escherichia coli BSI in a subject suspected of having a bacterial infection, the method comprising:
a) determining in a peripheral blood cell sample of the subject, the gene expression levels of two or more biomarkers selected from the group consisting of the biomarkers of Factor 20 and Factor 74 listed in Table 8 and Table 10, wherein the determined gene expression levels are RNA expression levels determined by microarray analysis, or PCR, or a combination thereof; and
b) administering an effective amount of appropriate antibacterial therapy to treat the subject identified as having a S. aureus BSI or E. coli BSI, wherein the subject is identified as having the S. aureus BSI or E. coli infection when the gene expression levels of the two or more biomarkers are different than the gene expression levels for the biomarkers in a control with known bacterial infection status.

7. The method of claim 6 , wherein the control is a subject having an E. coli BSI.

8. The method of claim 6 , wherein the subject is a mammal.

Assignees

• Univ Duke

Inventors

• Tsalik Ephraim
• Fowler Vance
• Woods Christopher W
• Lucas Joseph E
• Ginsburg Geoffrey S
• Ahn Sun Hee

Classifications

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q1/689

  for bacteria · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• C12Q2600/158

  Expression markers · CPC title